RESEARCH REPORT
Procter & Gamble Company (The)
PG
$161.57
As of 2026-11-01
Research note — 2026-11-01. Educational analysis, not financial advice.
The one-line version
Procter & Gamble Company (The) trades near $161.57 on a trailing multiple of about 24.3x versus its own 5-year median near 23.9x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~24.3 | ~23.9 | +2% |
| P/E (forward) | ~21.8 | — | — |
| EPS (TTM) | 6.64 | — | — |
| Gross margin | 50.6% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $158.73 — Applies the 5-year median multiple (23.9x) to trailing EPS.
- Street mean target: $173.65 — Average published analyst target.
- Street target midpoint: $170.50 — Midpoint of $151.00–$190.00 published range.
Street targets run from $151.00 to $190.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- Suze Orman Says You Don’t Have to transact in Every Market Dip. Here’s Why
- Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?
- If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- Coca-Cola and Procter & Gamble Are Up This Month. Which Dow Dividend Stock Is the Better bullish Now?
- 5 Dividend Stocks to transact in and neutral for the Next 5 Years
- 3 Dividend Stocks With Yields Up To 4%
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~24.3x rather than its 5-year ~23.9x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 2027-01-20
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-01 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 6, 2026|Here's How Many Shares of Procter & Gamble You'd Need for $1,000 in Yearly Dividends(Yahoo)
Even if generating $1,000 in dividend payouts from Procter & Gamble isn't in an investor's budget, it's still a stock worthy of investment consideration.
Nov 6, 2026|Dividend Champion, Contender, And Challenger Highlights: Week of November 8(SeekingAlpha)
Get the latest dividend activity for Dividend Champions, Contenders, and Challengers. Read this week's list here.
Nov 6, 2026|The Average 1-Year CD Pays Just 1.76%. These Dividend Stocks Could Pay More(Yahoo)
A guaranteed bank rate sounds safe until you weigh what it can't do. Six blue-chip payers offer income that can grow, but a board can cut it at any meeting, and the tax bill may decide which side comes out ahead.
Nov 6, 2026|4 Dividend Raisers With Balance Sheets Strong Enough to Keep Raising Through Any Downturn(Yahoo)
When profits dip, lenders get paid first and the dividend is usually what gets cut. Four household names have raised their payouts year after year, and one of them holds a credit rating almost no other U.S. company can match.
Nov 6, 2026|Coca-Cola vs P&G: Staples Rotation Crowns a Clear Income Winner(Yahoo)
Tech is bleeding while soda and detergent makers rally, and Jim Cramer wants to camp out in staples "for a bit." Two dividend legends have very different runs behind them, and only one suits someone living off portfolio income.
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
| Date | Executive | Action | Shares | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Schulten Andre (Chief Financial Officer) | Sell | 33,624 | $3.1M |
| Nov 4, 2026 | Schulten Andre (Chief Financial Officer) | Sell | 33,624 | $5.5M |
| Nov 4, 2026 | Schulten Andre (Chief Financial Officer) | Sell | 33,624 | $0 |
| Nov 3, 2026 | Janzaruk Matthew W. (SVP - Chief Accounting Officer) | Sell | 9,479 | $934,155.45 |
| Nov 3, 2026 | Janzaruk Matthew W. (SVP - Chief Accounting Officer) | Sell | 9,479 | $1.5M |
| Nov 3, 2026 | Janzaruk Matthew W. (SVP - Chief Accounting Officer) | Sell | 9,479 | $0 |
| Oct 30, 2026 | Gama Paul (CEO- Health Care) | Sell | 2,894 | $477,510 |
| Oct 30, 2026 | Aguilar Moses Victor Javier (Chf Rsch, Dev & Innov Officer) | Sell | 18,812 | $1.5M |
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| State Street | 102,216,308 | $15.0B | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.